SPECIALTY CARE 
ADA 2024 Poster: Trends in Guideline-Directed Medical Therapy for Type 2 Diabetes in a Statewide Quality Collaborative Between 2018-2023
Updated: 06/22/24
Presented at the American Diabetes Association Scientific Sessions, June 24, 2024, Orlando, Florida.
Poster Title: Trends in Guideline-Directed Medical Therapy frorType 2 Diabetes in a Statewide Quality Collaborative Between 2018-2023
DOI: 10.2337/db24-1073-P
Authors:
Kara Mizokami-Stout, MD [1,2]
Katherine L. Khosrovaneh, MPH [1]
Neha Bhomia, MHI [1]
Heidi L. Diez, PharmD, BCACP [1]
Dina Griauzde, MD [1,2]
Noa Kim, MSI [1]
Joyce M. Lee, MD [1]
Lauren Oshman, MD, MPH [1]
Jacqueline Rau, MHSA [1]
Jacob Reiss, MHSA [1]
Larrea Young, MDes [1]
Julian Weisensel, BFA [1]
Rodica Pop-Busui MD, PhD [1]
Affiliations:
[1] University of Michigan, Ann Arbor, MI, 48109
[2] Veteran Affairs Ann Arbor Healthcare System, Ann Arbor, MI 48105
Introduction and Objective: Since 2021, the Michigan Collaborative for Type 2 Diabetes (MCT2D) aims to improve guideline-directed medication therapies (GDMT) for type 2 diabetes (T2D). We examined trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose transport protein 2 inhibitor (SGLT2i) prescribing rates comparing primary care (PC) and endocrinology (Endo) practices enrolled in MCT2D.
Methods: We analyzed pharmacy claims data from adults with T2D insured by Blue Cross Blue Shield of Michigan Preferred Provider Organization and Medicare Advantage plans who received care in an MCT2D-participating practice (PC=300; Endo=19) between 2018-2023. Descriptive statistics were used to examine differences in pharmacy claims for anti-hyperglycemic medications.
Results: From June 2022-June 2023, among 38,437 persons with T2D (PC=37,361; Endo=1,076), 26% and 41% had claims for GLP-1RA and 19% and 37% for SGLT2i, respectively. Compared to 2018 prescription rates, GLP-1RA increased by 17% and 22%, while SGLT2i prescriptions increased by 15% and 28% in PC and Endo practices respectively (Figure 1).
Conclusion: Among practices participating in a statewide collaborative to improve treatment and outcomes for people with T2D, the use of GDMT has increased since 2018. SGLT2i use is similar and GLP-1RA use is 2-3-fold higher than rates reported in other studies.
Tags: Research, Created By MCT2D
Subscribe to the MCT2D Newsletter
Once per month we deliver news, updates, events, and more directly to you!
ccteam@mct2d.org
Support for The Michigan Collaborative for Type 2 Diabetes (MCT2D) is provided by Blue Cross Blue Shield of Michigan as part of the BCBSM Value Partnerships program.
Although Blue Cross Blue Shield of Michigan and MCT2D work collaboratively, the opinions, beliefs and viewpoints expressed by the author do not necessarily reflect the opinions, beliefs and viewpoints of BCBSM or any of its employees.